SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Billie Holiday

PatientBillie Holiday
Date of birth1993-04-07
IdentifiersMRN HR-ML010-SYN; SSN (made up) 000-10-4472
Document date2026-07-20
AuthorConstance Mayfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review after a return to opioid use six days ago. [S]

History of Present Illness

Ms. Holiday returns three months after starting buprenorphine. Eight days ago, on tour in another state, the pharmacy could not refill her buprenorphine because the insurer's prior authorization had lapsed. After two days without it she had withdrawal and strong cravings, and six days ago she used heroin twice. She tested the supply first and the fentanyl strip was positive; she used with her friend present and naloxone at hand, and she did not overdose. The pharmacy filled the prescription the next day, and she restarted buprenorphine that morning, after waiting until she felt withdrawal again as she had been taught; she has taken it daily since and has used no opioids for five days. She also drank more on the tour, most nights. She called the clinic as soon as she was home and wanted to be seen. She is ashamed and worried that she has lost her place in treatment. She has had no thoughts of suicide. She feels tired and low and has not been sleeping well. [S]

ElementDetail
Return to useHeroin twice, six days ago, after two days without buprenorphine
Cause of the gapLapsed prior authorization while on tour
SafetyTested the supply (fentanyl positive); used with her friend present and naloxone at hand; no overdose
BuprenorphineRestarted five days ago at 16 mg daily, without precipitated withdrawal
AlcoholDrinking most nights on tour
MoodTired, low, ashamed; PHQ-9 11; item 9 scored 0

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; weight down 1.2 kg; no fever
GastrointestinalNegativeNo nausea, vomiting, or diarrhea now
IntegumentaryNegativeNo injection-site redness or abscess
PsychiatricPositiveLow mood, poor sleep, and shame after the return to use; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue dailyOne film under the tongue daily after a 4 mg first doseSublingual route2026-04-20 to 2026-04-27completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once dailyTwo films under the tongue once dailySublingual route2026-04-27activeS
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no responseNasal route2026-04-20activeS
Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route2026-04-27activeS
Thiamine 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-10-19completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-20Body height165cmS
2026-07-20Body weight67.4kgS
2026-07-20Body mass index (BMI) [Ratio]24.8kg/m2S
2026-07-20Systolic blood pressure128mm[Hg]S
2026-07-20Diastolic blood pressure82mm[Hg]S
2026-07-20Heart rate86/minS
2026-07-20Respiratory rate16/minS
2026-07-20Body temperature36.8CelS
2026-07-20Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L10-40 U/LHighS
2026-07-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L7-56 U/LNormalS
2026-07-20Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma61U/L5-40 U/LHighS
2026-07-20Phosphatidylethanol [Mass/volume] in Blood164ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
2026-07-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]11{score}S

Physical Exam

Vital signs recorded on 2026-07-20; see the Vital Signs section. [S]

SystemFinding
GeneralTired but well; blood pressure 128/82, pulse 86
SkinNo injection marks, redness, or abscess
EyesPupils normal in size; no signs of withdrawal
PsychiatricTearful at first, then engaged in planning; no signs of intoxication

Problems

ProblemClinical statusVerificationCodeProvenance
Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin useactiveconfirmed F11.20S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use.
Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's deathactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, adherence, cravings, withdrawal, and side effectsEvery visitCompleted todayGap of three days from a lapsed prior authorization, then restarted at 16 mg; no precipitated withdrawal
Self-managementVisit frequencyEvery 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stableCompleted todayVideo check-ins every two weeks kept since the five-week visit; seen in person within days of her call
LaboratoryUrine drug testing, including fentanyl, explained as part of care rather than as a test of trustAt the start, then about monthly early in treatment and as neededCompleted todayBuprenorphine, norbuprenorphine, and norfentanyl, consistent with what she reported
Medication safetyPrescription drug monitoring program checkBefore each buprenorphine prescriptionCompleted todayNo other prescriptions
Medication safetyNaloxone at home and in her bag, and a trained companionAt the start; check and replace at each visitCompleted todayNot used; replaced with new test strips
Self-managementOverdose prevention: never using alone and fentanyl test stripsEvery visitCompleted todayShe tested the supply and used with a companion and naloxone; reinforced without judgment
Medication safetyPrescription continuity on tour (pharmacy, prior authorization, travel letter)Before each tourCompleted todayPrior authorization renewed for twelve months; national pharmacy chain; early fill and travel letter
Self-managementCounseling and peer recovery supportOffered to everyone; not a condition of medicationCompleted todayWeekly in-person counseling from now; peer coach
SurveyDrinking and PEthPEth at intake and at each check while drinking continues; AUDIT-C yearlyCompleted todayPEth 164 ng/mL, up from 96, with heavier drinking on tour
Medication safetyAcamprosate adherence and kidney functionKidney function before starting; adherence every visitCompleted todayTaking it; midday reminder working
Medication safetyThiamineWhile drinking heavilyCompleted todayTaking thiamine daily
LaboratoryLiver tests (AST, ALT, GGT, albumin, bilirubin)At intake, then every 1 to 3 months while drinking is heavy, and yearlyCompleted todayAST 44, ALT 33, GGT 61 U/L
LaboratoryFIB-4 fibrosis scoreAt intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 yearsUp to date1.18 at intake; repeat at six months
SurveyDepression screen (PHQ-9)At intake and at each recovery visit while symptoms are presentCompleted todayPHQ-9 11, item 9 scored 0; interview does not show a depressive episode
SurveyMood Disorder QuestionnaireAt the evaluation of a new depressive episodeNot indicatedNo depressive episode on interview and no history suggesting mania
SurveySuicide and overdose risk review, safety plan, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; overdose risk after the gap reviewed; the safety plan updated; the 988 Suicide & Crisis Lifeline in her phone

Goal progress:

Guideline basis: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Weekly counseling. Preventive visit in six weeks with the PHQ-9. Call the clinic the same day if a refill fails or cravings rise. Next scheduled visit 2026-08-31: periodic adult preventive visit. [S]